Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174.
McCrea
J B
JB
Merck Research Laboratories, West Point, Clinical Pharmacology, PA 19486, USA.
Cribb
A
A
Rushmore
T
T
Osborne
B
B
Gillen
L
L
Lo
M W
MW
Waldman
S
S
Bjornsson
T
T
Spielberg
S
S
Goldberg
M R
MR
D000328:Adult; D000483:Alleles; D000889:Anti-Arrhythmia Agents / Q000378:metabolism*; D000959:Antihypertensive Agents / Q000378:metabolism*; D001189:Aryl Hydrocarbon Hydroxylases; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D005838:Genotype; D006801:Humans; D007093:Imidazoles / Q000378:metabolism*; D019808:Losartan / Q000378:metabolism*; D008297:Male; D006899:Mixed Function Oxygenases / Q000235:genetics*; D010641:Phenotype; D012016:Reference Values; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000235:genetics*; D013777:Tetrazoles / Q000378:metabolism*; D014838:Volunteers
D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D007093:Imidazoles; D013777:Tetrazoles; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D013250:Steroid Hydroxylases; D001189:Aryl Hydrocarbon Hydroxylases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D039181:Steroid 16-alpha-Hydroxylase; C066026:losartan carboxylic acid; D019808:Losartan